Monitor for clinical validation data, regulatory updates, and any future financial commitments from this collaboration. No near-term revenue impact expected; the stock may see speculative moves on development milestones.
Price Chart
Executive Summary
bioAffinity Technologies announced a collaboration with Pictor, Inc. to develop and commercialize next-generation diagnostic tests for asthma and COPD, integrating bioAffinity's flow cytometry with Pictor's proteomic platform. No financial terms or milestones were disclosed; the tests remain in development and will initially be offered as laboratory developed tests (LDTs).
Key Facts
- Partnership with Pictor, Inc. to develop diagnostic tests for asthma and COPD using sputum analysis and targeted proteomics.
- Tests are intended to match patients with personalized treatments by measuring immune cell populations and cytokine profiles.
- bioAffinity retains IP for its test inventions; Pictor retains IP for its platform technology.
- Tests will be initially offered as Laboratory Developed Tests (LDTs) under CLIA.
- No financial terms, upfront payments, or revenue guidance disclosed.
Financial Impact
No financial terms disclosed; collaboration is non-binding on revenue.
Risk Factors
- Tests are in early-stage development and may not achieve commercialization.
- Regulatory landscape for LDTs is evolving, with potential FDA clearance requirements.
- Company has limited operating history and history of losses; may need additional capital.
- Collaboration may not achieve anticipated benefits or could be terminated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-034183 |
| Exhibit: ex99-1.htm | 0001493152-26-034183 |
| Document: 0001493152-26-034183-index-headers.html | 0001493152-26-034183 |
| Document: 0001493152-26-034183-index.html | 0001493152-26-034183 |
| Document: 0001493152-26-034183.txt | 0001493152-26-034183 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | DEF 14A | $2.83 | awaiting T+60 | — | $2.96 (+4.59%) |
Oct 15, 2026 12d ago | 8-K | $3.96 | awaiting T+60 | — | $2.96 (−25.25%) |
Oct 13, 2026 14d ago | 8-K | $3.63 | awaiting T+60 | — | $2.96 (−18.34%) |
Oct 9, 2026 18d ago | 8-K | $3.90 | awaiting T+60 | — | $2.96 (+24.10%) |
Oct 9, 2026 18d ago | 424B5 | $4.73 | awaiting T+60 | — | $2.96 (+37.35%) |
Oct 9, 2026 18d ago | 424B5 | $4.73 | awaiting T+60 | — | $2.96 (−37.35%) |
Oct 8, 2026 19d ago | 8-K | $5.64 | awaiting T+60 | — | $2.96 (−47.52%) |
Oct 6, 2026 21d ago | 8-K | $6.06 | awaiting T+60 | — | $2.96 (−51.16%) |
Sep 30, 2026 27d ago | 8-K | $6.56 | awaiting T+60 | — | $2.96 (−54.88%) |
Sep 22, 2026 5w ago | 8-K | $8.56 | awaiting T+60 | — | $2.96 (−65.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers